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Preoperative staging of gastric cancer is difficult and not optimal. The TNM stage is an important prognostic factor, but it can only be
assessed reliably after surgery. Therefore, there is need for additional, reliable prognostic factors that can be determined
preoperatively in order to select patients who might benefit from (neo) adjuvant treatment. Expression of immunohistochemical
markers was demonstrated to be associated with tumour progression and metastasis. The expression of p53, CD44 (splice variants
v5, v6 and v9), E-cadherin, Ep-CAM (CO17-1A antigen) and c-erB2/neu were investigated in tumour tissues of 300 patients from the
Dutch Gastric Cancer Trial, investigating the value of extended lymphadenectomy compared to that of limited lymphadenectomy).
The expression of tumour markers was analysed with respect to patient survival. Patients without loss of Ep-CAM-expression of
tumour cells (19%) had a significantly better 10-year survival (Po0.0001) compared to patients with any loss: 42% (s.e.¼ 7%) vs 22%
(s.e.¼ 3%). Patients with CD44v6 (VFF18) expression in more than 25% of the tumour cells (69% of the patients) also had a
significantly better survival (P¼ 0.01) compared to patients with expression in less than 25% of the tumour cells: 10 year survival rate
of 29% (s.e.¼ 3%) vs 19% (s.e.¼ 4%). The prognostic value of both markers was stronger in stages I and II, and independent of the
TNM stage. Ep-CAM and CD44v6-expression provides prognostic information additional to the TNM stage. Loss of Ep-CAM-
expression identifies aggressive tumours especially in patients with stage I and II disease. This information may be helpful in selecting
patients suitable for surgery or for additional treatment pre- or postoperatively.
British Journal of Cancer (2005) 92, 1767–1772. doi:10.1038/sj.bjc.6602519 www.bjcancer.com
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Patients with gastric carcinoma have a poor prognosis, especially
the patients with an advanced stage disease (Allum et al, 1989;
Akoh et al, 1991; Wanebo et al, 1993). In TNM stages I and II,
better survival rates are seen after a curative resection: 5 year
survival rates of 83–99% for stage I and 48– 70% in stage II (Miwa,
Japanese Research Society for Gastric Cancer, 1984; Hermanek,
1985). The TNM stage thus is an important prognostic factor, but it
can be assessed reliably only after surgery and is therefore of no
use for patient selection before surgery. Furthermore, within stages
I and II, a significant number of patients will suffer from recurrent
disease. Especially within this group there is a need for additional
prognostic factors that can be determined preoperatively. Such
factors are potentially helpful in identifying patients that might
benefit from additional therapeutic modalities, either pre- or post-
operatively (Yu et al, 1998; Hermans et al, 1999).
The process of carcinogenesis and metastasis is complex. Since
we were interested in factors, which can predict whether the
tumour is beyond cure by surgery alone, we reasoned that
especially molecules involved in cell –cell and cell –extracellular
matrix (ECM) interactions might be of high relevance. CD44, a
hyaluronate receptor, is involved in cell migration through the
ECM, which can be viewed as highly relevant for tumour invasion
and metastasis. Previous studies have indicated that CD44 isoform
expression may be related to gastric tumour progression and poor
prognosis for the patient (Heider et al, 1993; Mayer et al, 1993;
Mulder et al, 1994; Terpe et al, 1994; Gu¨nthert et al, 1995). Given
the fact that progression of tumours is modulated by changes in
cell–cell interactions of the progressing tumour clones, we
especially focused on the expression of Ep-CAM, an epithelial cell
adhesion molecule, involved in regulation of cadherin adhesions,
and, possibly, cell proliferation and invasion (Litvinov et al,
1994a, b; Litvinov, 1995). Furthermore, we analysed whether the
expression of two molecules often involved in gastric cancer, p53
(involved in cell cycle control and apoptosis, and often over-
expressed when mutations are present) and neu (or erbB2, a
receptor tyrosine kinase that can be overexpressed due to the gene
amplification, Falck and Gullick, 1989; Houldsworth et al, 1990)
might be associated with prognosis in gastric cancer, even though
they are presumably associated with early events in gastric
carcinogenesis.
Evaluation of prognostic factors has to be based on high quality
clinical and pathological data. In the Netherlands, a prospectively
Received 16 August 2004; revised 7 February 2005; accepted
21 February 2005
*Correspondence: Dr H van Krieken, Department of Pathology,
Radbond University, Nijmegen Medical Center, PO Box 9101, 6500
HB Nijmegen, The Netherlands; E-mail: j.vankrieken@pathol.umcn.nl
British Journal of Cancer (2005) 92, 1767 – 1772
& 2005 Cancer Research UK All rights reserved 0007 – 0920/05 $30.00
www.bjcancer.com
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
randomised, multicenter trial was conducted to compare the
therapeutic efficacy of extended lymph node dissection with
limited lymph node dissection in patients with gastric cancer
(Bonenkamp et al, 1995, 1999). Strict quality control measures
were taken to obtain optimal lymph node retrieval and thus
postoperative staging. The prospectively collected clinical and
pathology data from this trial form an optimal basis to evaluate the
usefulness of prognostic value of immunohistochemically deter-
mined protein expression in tumour cells.
MATERIAL AND METHODS
Patient selection
Between August 1989 and July 1993 a prospective randomised
multicenter trial was conducted in the Netherlands (Dutch Gastric
Cancer Trial, DGCT) to compare the therapeutic efficacy of
extended lymph node dissection (N1 and N2 levels, so-called D2)
with that of limited lymph node dissection (N1 level, so-called D1)
in patients with gastric cancer, operated on with curative intent
(R0). For these patients (criteria for curative resectability were
published earlier, Bonenkamp et al, 1995, 1999), presence of nodal
involvement was assessed histologically and the pathologist
recorded the actual number and location of the lymph nodes
retrieved. Follow-up of the patients is at least 10 years.
In the present study, tumour tissue of 300 patients was used.
Selection of these patients was based on the hospitals entering the
largest number of patients, in order to have minimal variability in
preparation and preservation of patient material used in this study.
Immunohistochemistry
In order to evaluate protein expression in adenocarcinoma of the
stomach, formalin-fixed, paraffin-embedded tissue blocks of the
primary tumour were used. According to the allocated treatment,
the specimens were obtained by D1 or D2 resection. If a curative
resection in intent was not possible, a palliative procedure was
performed. From each resection specimen one tissue block was
selected that contained the largest amount of tumour.
Sections (4-mm thick) were cut from formalin-fixed, paraffin-
embedded tissue blocks, mounted on precoated slides and kept at
371C overnight. All paraffin sections were dewaxed in xylol for
20 min and endogenous peroxidase activity was blocked by
methanol/H2O2.
The monoclonal antibodies of the following specificities were
used: cell cycle regulator p53 (mAb NCL-p53-DO7, Novocastra
Laboratories Ltd), Ep-CAM (mAb 323/A3, Centocor, Malvern, PA,
USA), E-Cadherin (mAb HECD-1, Thamer Diagnostica B.V.),
CD44, splice variant v5 (VFF8), v6 (VFF7 and VFF18)9, and v9 (all
from Bender Co., Vienna, Austria) and neu (Department of
Pathology, Leiden). In negative controls, the primary antibody was
replaced by phosphate-buffered saline (PBS).
For Ep-CAM staining, the sections were pretreated with a
trypsin-solution (0.1% trypsin with 0.1% CaCl2), pH 7.4, at 371C
for 20 min. For p53, E-cadherin, CD44 variants and neu staining,
the sections were pretreated by microwave in citrate buffer (pH
6.0) for 25 min. The pretreated sections were rinsed in PBS and
blocked by normal goat serum to reduce nonspecific antibody
binding. The primary antibody was then applied and incubated
overnight in its optimal dilutions in PBS/1% bovine serum
albumin (BSA).
The sections were washed with PBS prior to incubation with the
secondary antibody. Then, a double step detection system was
used: biotinylated rabbit anti-mouse (RAM) IgG was followed by
streptavidin-biotin-complexHRP (sABC); each incubation was for
45 min. The slides were stained with 3,30-diaminobenzidine/H2O2
(DAB) solution, and counterstained with Mayer’s haematoxylin.
Scoring of the sections
The expression of the proteins was scored according to the
estimated percentage tumour cells in the total tissue section
showing positive staining. For each marker a scoring system was
developed after initial screening of the variation of expression of
each marker and taking systems used in the literature in account.
This resulted in the following categories: p53 (0: 0 –10%; 1: X10–
100%); VFF8, VFF7 and NEU (0: negative; 1: positive); CD44v9 (0:
0–5%; 1: X5– 100%); VFF18 (0: 0–25%; 1: X25–100%); E-
Cadherin (0: o50%; 1: X50%) and Ep-CAM (0: negative; 1: 1–
99%; 2: 100%).
The scoring was done by two independent observers (IS and
JHJMvK). Discrepancies were solved and consensus was reached
by using a double-headed microscope. Incidentally, the marker
scorings could not be performed because of missing material.
Clinical data were provided after obtaining immunohistochemical
results.
Statistical analysis
For statistical analysis the SPSS program was used. Kaplan–Meier
survival curves are compared using the log-rank test. Cox’s
Table 1 TNM stage and marker expression related to overall survival
Overall survival
Marker expression n (%)
5 year
%
10 year
%
P-value
(log-rank)
TNM-stage (n¼ 285)
I 97 (34) 74 58
II 61 (21) 36 26
III 76 (27) 12 6 o0.001
IV 50 (18) 6 4
p53 (n¼ 286)
0–10% positive 146 (51) 36 27
X10% positive 140 (49) 35 25 0.85
CD44v9 (n¼ 286)
0–5% positive 148 (52) 37 27
X5% positive 138 (48) 33 25 0.23
VFF8 (v5) (n¼ 282)
Negative 115 (41) 35 24
Positive 167 (59) 36 27 0.84
VFF18 (v6) (n¼ 285)
0–25% positive 89 (31) 24 19
26–100% positive 196 (69) 41 29 0.01
VFF7 (v6) (n¼ 284)
Negative 220 (78) 38 28
Positive 64 (22) 27 19 0.11
NEU (n¼ 289)
Negative 263 (91) 35 26
Positive 26 (9) 31 23 0.98
E-Cadherin (n¼ 281)
0–49% positive 146 (52) 34 25
50– 100% positive 135 (48) 35 24 0.63
Ep-CAM (n¼ 280)
Negative 20 (7) 10 5
1–99% positive 208 (74) 32 22 o0.001
100% positive 52 (19) 54 42
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regression was used to study the prognostic value for survival of
tumour marker combinations. Differences were considered
statistically significant, when the P-value was less than 0.05.
RESULTS
The study group consisted of 181 male and 119 female patients.
Mean age was 64.7 years (range 31–84). Of these patients, 154
received a D1 and 146 D2 lymphadenectomy; 254 patients (85%)
had a resection with curative intent and the remaining 46 patients
(15%) had noncurative procedures. As expected, the TNM stage
(not always available in noncurative procedures) was highly
prognostic (see Table 1).
Based on univariate analyses of the original scoring of the
markers, all marker expressions were dichotomised into more or
less equal groups. Only Ep-CAM is divided into three groups: 1,
negative; 2, any loss of expression (1–99% positive) and 3, no loss
of expression (100% positive). The results are reported in Table 1.
Examples of the staining patterns for E-cadherin and CD44v6
are shown in Figure 1.
From all the markers tested, only CD44v6 (VFF18 antibody) and
Ep-CAM had a statistically significant prognostic value for survival
(see Table 1 and Figures 2 and 3).
As a curative resection in intent is an important prognostic
factor itself, we analysed this group separately. Again, only the
TNM stage, CD44v6 (VFF18) and Ep-CAM had a strong prognostic
value (Table 2).
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Figure 1 Examples of staining for CD44v6 (VFF18), E-Cadherin and Ep-CAM. Case 1: all cells are staining for Ep-CAM (A), no staining for E-Cadherin (C)
and partial loss for CD44VFF18 (E). Case 2 shows only little staining for Ep-CAM (B), staining in more than 90% of the tumour cells for E-Cadherin, (D)
whereas there is also more than 90% staining for CD44vvf18 (F).
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The prognostic value of the markers was studied additional to
the TNM stage with a stepwise Cox’s regression analysis. For this
analysis the TNM stage was dichotomised into stages Iþ II vs
stages IIIþ IV. Both CD44v6 (VFF18) and Ep-CAM were selected
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Figure 2 Survival of patients in whom more than 25% of the tumour
cells stain for CD44v6 (VFF18) compared to those with less staining.
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Figure 3 Survival curves of the three groups of patients with no staining
for Ep-CAM compared to those with no loss and the intermediate group.
Table 2 Association between TNM stage, VFF18 and Ep-CAM
expression and survival in patients with a curative resection in intent
Overall survival
P-value
N (%) 5 year % 10 year % (log-rank)
TNM-stage (n¼ 251)
I 97 (39) 73 58
II 61 (25) 36 26
III 77 (30) 12 6
IV 16 (6) 19 13 o0.0001
VFF18 (n¼ 240)
0–25% 74 (31) 28 23
26–100% 166 (69) 48 34 0.01
Ep-CAM (n¼ 236)
0 15 (6) 13 7
1–99% 174 (74) 38 26 o0.001
100% 47 (20) 60 47
Table 3 Cox’s regression analysis applied on TNM stage, VFF18 and Ep-
CAM expression (n¼ 251)
RR 95% CI P-value
TNM stage
I+II 1.00 2.27–4.29 o0.001
III+IV 3.12 1.01–2.00 0.04
VFF18
26–100% 1.00 0.99–2.31 0.05
0–25% 1.42 0.96–4.14 0.06
Ep-CAM
100% 1.00
1–99% 1.51
0% 1.99
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Figure 4 (A) Survival curve of the three groups divided by Ep-CAM
staining for stages Iþ II patients only, showing that even patients with low
stage disease, but with complete loss op Ep-CAM have very poor
prognosis. (B) Survival curve of the three groups divided by Ep-CAM
staining for stages IIIþ IV patients only, showing no significant differences.
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as having a significant prognostic value additional to the TNM
stage (Table 3).
The prognostic value of the markers is especially evident in the
stages I and II, see Figure 4A. In stages III and IV, the survival rates
are very poor, so Ep-CAM expression cannot reach a statistically
significant difference between the groups, see Figure 4B. Also,
CD44v6 (VFF18) expression has prognostic relevance especially in
early stages, see Figure 5.
DISCUSSION
Our study demonstrates that loss of Ep-CAM and CD44v6 (VFF18)
expression in gastric cancer has additional prognostic value to the
TNM stage. If confirmed, these findings can be helpful in selecting
patients for (neo-)adjuvant therapy for gastric cancer (Yu et al,
1998; Hermans et al, 1999).
Although Ep-CAM is present in many epithelial cell types, some,
like squamous epithelia express this molecule only in embryogen-
esis or in neoplasia (reviewed by Litvinov, 1995). In gastric
epithelium the expression of Ep-CAM is low, and its increase is
associated with very early stages of development of intestinal
metaplasia (unpublished data). However, Ep-CAM loss associated
with poor prognosis, as demonstrated in our earlier (Songun et al,
1996) and the present study, differs from previous observations of
increased Ep-CAM expression associated with poor prognosis in
breast cancer (Mirecka et al, 1995). Although not very strong, Ep-
CAM mediated adhesions were able to suppress the scattering of
cells embedded into matrigel (Litvinov, 1995). It was also
demonstrated that in carcinoma cells with low levels of E-cadherin,
a role for Ep-CAM adhesions in interconnecting cells is increasing
(Tandon et al, 1990; Basak et al, 1998). Basak et al (1998) showed
that in a model system Ep-CAM mediated adhesion can suppress
invasion of tumour cells grafted in mice. Therefore, it seems quite
possible that Ep-CAM negative cells are greatly reduced in means
of cell –cell adhesion, which promotes their metastasis. However,
we did not find a prognostic impact for E-cadherin expression, in
concordance with findings in colorectal cancer (Van der Wurff
et al, 1992, 1997). No studies have been carried out on gastric
cancer previously, except for hereditary diffuse gastric cancer,
which is extremely rare (Suriano et al, 2003).
CD44 is a highly glycosylated cell surface molecule, which is
involved in cell–cell and cell –matrix interactions (Haynes et al,
1989, 1991). It was proven that transfection with cDNA encoding
one isoform of CD44 converted nonmetastatic carcinoma and
sarcoma rat cells into metastatic cells (Gu¨nthert et al, 1991). In
human, high CD44 expression was shown to correlate with tumour
dissemination and poor prognosis in diffuse large cell lymphoma
and in colorectal carcinoma (Koopman et al, 1993; Mulder et al,
1994). CD44 variants containing v6 were also upregulated in
activated lymphocytes (Koopman et al, 1993). However, it was also
reported that CD44v6 is downregulated in tumours of squamocel-
lular origin. Also, better differentiated carcinomas displayed more
intense reactivity than more undifferentiated ones (Salmi et al,
1993). Our data are in line with previous studies (Mirecka et al,
1995; Muller et al, 1997). Both in the latter studies and in our study
there was no association between CD44v6 expression (with VFF18)
and presence of lymph node metastasis or tumour stage (data not
shown). Our results suggest that CD44v6 would not be responsible
for invasive growth and metastasis formation. They rather suggest
that CD44v6 containing tumours behave less aggressively,
illustrated by the fact that they are associated with significantly
better survival. However, the VFF7 antibody, which is less sensitive
in detecting CD44v6, was staining far fewer tumour cells and its
expression was less strong compared to the VFF18 antibody. This
shows the importance of selection of the right antibodies in studies
like the present one.
The large amount of studies on p53 as prognostic marker gives
very variable results. Our study, using just immunohistochemistry,
the only generally applicable method, does not show clinical
relevance. Our findings suggest the following biological implica-
tions: loss of p53 protein or E-cadherin is an early event during
oncogenesis and therefore not predictive of a metastatic behaviour
(Van der Wurff et al, 1992), whereas CD44 (v6) and Ep-CAM are
late events, since Ep-CAM is positive in lymph node metastasis in
patients with loss of Ep-CAM at the invasive front (unpublished
observations). This suggests that the loss we observed is not a
genetic defect, but rather reflects the complex interactions of
angiogenesis, adhesion, matrix degradation and inflammation,
which take place during the process of invasion and metastasis.
We have demonstrated that Ep-CAM and CD44v6 provide
prognostic information additional to the TNM stage in a large
series of gastric cancer patients with well documented, prospec-
tively collected data from a randomised trial (Bonenkamp et al,
1995, 1999). Both CD44v6 and Ep-CAM expression may be helpful
in identifying behaviour of gastric adenocarcinoma. This informa-
tion may be helpful in selecting patients suitable for surgery or for
additional treatment pre- or postoperatively. However, additional
studies are required to establish the place of these markers in
clinical management of patients with gastric cancer.
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